Sarepta

Latest articles

6d
FOX Business
These Biotech Stocks Are Pricey, but Investors Can Still Buy ThemSarepta Therapeutics(NASDAQ: SRPT) and Amicus Therapeutics(NASDAQ: FOLD) are tw
FOX Business / Posted 6 days ago
Sarepta Therapeutics(NASDAQ: SRPT) and Amicus Therapeutics(NASDAQ: FOLD) are two fast-growing biotech stocks that are trading at price-to-sales multiples north of 50, yet biotech investors may still want to add them to their portfolios despite their... Read more
6d
FOX Business
These Biotech Stocks Are Pricey, but Investors Can Still Buy ThemSarepta Therapeutics(NASDAQ: SRPT) and Amicus Therapeutics(NASDAQ: FOLD) are tw
FOX Business / Posted 6 days ago
Sarepta Therapeutics(NASDAQ: SRPT) and Amicus Therapeutics(NASDAQ: FOLD) are two fast-growing biotech stocks that are trading at price-to-sales multiples north of 50, yet biotech investors may still want to add them to their portfolios despite their... Read more
12d
FOX Business
What Caused Sarepta Therapeutics to Rally 12.6% in Septemberearly-stage data from a drug candidate for the treatment of Duchenne muscular d
FOX Business / Posted 12 days ago
early-stage data from a drug candidate for the treatment of Duchenne muscular dystrophy (DMD) on September 6, shares in Sarepta Therapeutics(NASDAQ: SRPT) jumped 12.6% last month, according to S&P Global Market Intelligence. So what DMD is a... Read more
3 related articles
12d
FOX Business
What Caused Sarepta Therapeutics to Rally 12.6% in Septemberearly-stage data from a drug candidate for the treatment of Duchenne muscular d
FOX Business / Posted 12 days ago
early-stage data from a drug candidate for the treatment of Duchenne muscular dystrophy (DMD) on September 6, shares in Sarepta Therapeutics(NASDAQ: SRPT) jumped 12.6% last month, according to S&P Global Market Intelligence. So what DMD is a... Read more
3 related articles
15d
Market Watch
Sarepta Therapeutics shares surge 7.5% after Morgan Stanley upgradeSarepta Therapeutics Inc. SRPT, +6.39% shares surged 7.5% in heavy morning trad
Market Watch / Posted 15 days ago
Sarepta Therapeutics Inc. SRPT, +6.39% shares surged 7.5% in heavy morning trade Monday after the company was upgraded to overweight by Morgan Stanley with a $60 price target. Sarepta shares were valued at $48.68 as of Monday morning. "We expect... Read more
15d
Market Watch
Investors want PTC Therapeutics to be the next Sareptamuscle weakness. It primarily affects boys early in their childhood, and typica
Market Watch / Posted 15 days ago
muscle weakness. It primarily affects boys early in their childhood, and typically kills patients before age 30. Sarepta was the first U.S.-approved medication for DMD; PTC Therapeutics PTCT, +14.60% now owns Emflaza, another DMD drug... Read more
17d
FOX Business
The Unusual Reason PTC Therapeutics, Inc. Is Bouncing Back Todayon the rise on Friday. A slight glimmer of hope the FDA might ignore the panel'
FOX Business / Posted 17 days ago
on the rise on Friday. A slight glimmer of hope the FDA might ignore the panel's recommendation, as it did a year ago for Sarepta Therapeutics(NASDAQ: SRPT), or eventually approve the drug, lifted the stock 12% higher as of 11:47 a.m. EDT... Read more
17d
FOX Business
The Unusual Reason PTC Therapeutics, Inc. Is Bouncing Back Todayon the rise on Friday. A slight glimmer of hope the FDA might ignore the panel'
FOX Business / Posted 17 days ago
on the rise on Friday. A slight glimmer of hope the FDA might ignore the panel's recommendation, as it did a year ago for Sarepta Therapeutics(NASDAQ: SRPT), or eventually approve the drug, lifted the stock 12% higher as of 11:47 a.m. EDT... Read more
17d
Market Watch
Sarepta Therapeutics shares dive on safety issues in FDA databaseSarepta Therapeutics Inc. SRPT, -3.03% shares declined as much as 8% in morning
Market Watch / Posted 17 days ago
Sarepta Therapeutics Inc. SRPT, -3.03% shares declined as much as 8% in morning trade Friday on safety issues reported in the Food and Drug Administration's Adverse Events Reporting System (FAERS) for the company's controversial Exondys 51 therapy.... Read more
20d
FOX Business
Here's Why PTC Therapeutics, Inc. Is Slipping Todaydoesn't look like the advisory committee has much to work with. There's a chanc
FOX Business / Posted 20 days ago
doesn't look like the advisory committee has much to work with. There's a chance the company might slide through the door Sarepta opened with Exondys 51 last year, but betting on another controversial approval isn't a sound investment strategy.... Read more
20d
FOX Business
Here's Why PTC Therapeutics, Inc. Is Slipping Todaydoesn't look like the advisory committee has much to work with. There's a chanc
FOX Business / Posted 20 days ago
doesn't look like the advisory committee has much to work with. There's a chance the company might slide through the door Sarepta opened with Exondys 51 last year, but betting on another controversial approval isn't a sound investment strategy.... Read more
21d
FOX Business
3 Biotech Stocks With Major Catalysts in Octobercatalysts that could help -- or possibly hurt -- Alexion Pharmaceuticals(NASDAQ
FOX Business / Posted 21 days ago
catalysts that could help -- or possibly hurt -- Alexion Pharmaceuticals(NASDAQ: ALXN), bluebird bio(NASDAQ: BLUE), and Sarepta Therapeutics(NASDAQ: SRPT). Alexion Pharmaceuticals Alexion became one of the most successful biotechs in the world... Read more
21d
FOX Business
3 Biotech Stocks With Major Catalysts in Octobercatalysts that could help -- or possibly hurt -- Alexion Pharmaceuticals(NASDAQ
FOX Business / Posted 21 days ago
catalysts that could help -- or possibly hurt -- Alexion Pharmaceuticals(NASDAQ: ALXN), bluebird bio(NASDAQ: BLUE), and Sarepta Therapeutics(NASDAQ: SRPT). Alexion Pharmaceuticals Alexion became one of the most successful biotechs in the world... Read more
25d
FOX Business
3 Biotech Stocks With Major Catalysts Incominga rundown of upcoming events that will alter perceptions of their candidates' p
FOX Business / Posted 25 days ago
a rundown of upcoming events that will alter perceptions of their candidates' potential in the days and weeks ahead. In Sarepta's footprints Citing a lack of efficacy data, the U.S. Food and Drug Administration initially refused to file PTC... Read more
25d
FOX Business
3 Biotech Stocks With Major Catalysts Incomingevents that will alter perceptions of their candidates' potential in the days a
FOX Business / Posted 25 days ago
events that will alter perceptions of their candidates' potential in the days and weeks ahead. Continue Reading Below In Sarepta's footprints Citing a lack of efficacy data, the U.S. Food and Drug Administration initially refused to file PTC... Read more

In this news